CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acrongenomics Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acrongenomics Inc.
Fairfax House, 15 Fulwood Place
Phone: +30 6977243620p:+30 6977243620 LONDON, ENG  WC1V 6AY  United Kingdom Ticker: AGNM AGNM

On 4/23/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Acrongenomics Inc. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.

Business Summary
Acrongenomics, Inc. (Acrongenomics) is a development-stage company. The Company focuses on investing and commercializing technology platforms concerning the life sciences sector. As of December 31, 2010, the Company held approximately 17.2% of the issued and outstanding shares of Molecular Vision Limited (Molecular Vision). The Company’s subsidiary, Vardisto Investments Limited’s assets are its ownership interest in Halldale Ventures Limited (Halldale) and Irwingom Ventures Limited (Irwingom). Halldale and Irwingom are Cyprus private companies, in which Vardisto holds an 80% and 65% interest respectively. During the year ended December 31, 2010, the Company wrote-off its investment in Molecular Vision to a nominal amount. On December 29, 2010, the Company completed the acquisition of 100% of the total outstanding share capital of Vardisto Investments Limited.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201112/31/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Evan T.Manolis 54 9/2/2008 5/8/2007
President, Director PlatonTzouvalis 46 10/5/2006 2/14/2005
Chief Financial Officer, Director RonaldLizee 52 6/4/2004 6/4/2004

Business Names
Business Name
Acrongenomics Inc.
AGNM
CELLWAY VENTURES INC
CWYV

General Information
Number of Employees: 2 (As of 3/31/2010)
Outstanding Shares: 30,205,086 (As of 8/8/2012)
Shareholders: 226
Stock Exchange: OTC
Federal Tax Id: 522219285


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023